Skip to content
Peptigraph home

Orforglipron Side Effects: What Studies and Users Report

What FDA labels, clinical studies and people who use Orforglipron report, how strong that evidence is, and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureOral small-molecule GLP-1 agonistUpdated

Side effects reported in studies

Adverse reactions from the FDA label come first, then side effects reported in individual studies. Frequencies are quoted as the source gives them; animal results are labelled.

Side effects of Orforglipron in labels and published studies
Side effectHow commonStudy typeSource
Most common adverse reactions (5% or more)5% or more of patientsFDA labelFDA label (Foundayo)
Nausea (placebo, 5.5 mg, 9 mg, 17.2 mg)placebo 10%; 5.5 mg 26%; 9 mg 34%; 17.2 mg 35%FDA labelFDA label (Foundayo)
Vomiting (placebo, 5.5 mg, 9 mg, 17.2 mg)placebo 4%; 5.5 mg 13%; 9 mg 21%; 17.2 mg 24%FDA labelFDA label (Foundayo)
Gastrointestinal events and discontinuation59% and 58% (orforglipron) vs 37% and 45% (oral semaglutide)Human controlled trialn = 1698Lancet 2026, PMID 41765029
Gastrointestinal events47%, 46%, 54% (3, 12, 36 mg) vs 12% dapagliflozinHuman controlled trialn = 962Lancet 2026, PMID 42259339
Gastrointestinal eventsmost commonHuman RCTn = 376Nature medicine 2026, PMID 42120723
Gastrointestinal eventsmost commonHuman RCTn = 616Obesity pillars 2026, PMID 42577069
Gastrointestinal eventsmost commonHuman RCTn = 3127The New England journal of medicine 2025, PMID 40960239
Severe hypoglycemianone reportedHuman RCTn = 559The New England journal of medicine 2025, PMID 40544435
Gastrointestinal eventsdiscontinuation in 10 to 17% of participantsHuman RCTn = 272The New England journal of medicine 2023, PMID 37351564
Gastrointestinal events44·1% to 70·4% (orforglipron) vs 18·2% (placebo)Human RCTn = 383Lancet 2023, PMID 37369232
Gastrointestinal eventsmost commonHuman RCTn = 92Diabetes, obesity & metabolism 2023, PMID 37344954
Gastrointestinal eventsmost commonHuman RCTn = 68Diabetes, obesity & metabolism 2023, PMID 37264711
Gastrointestinal eventsmost commonMeta-analysisn = 815Archives of endocrinology and metabolism 2024, PMID 39420937

Overall safety findings

What studies said about safety as a whole, without naming a specific effect.

Overall safety findings for Orforglipron in published studies
FindingHow commonStudy typeSource
Discontinuation due to adverse reactions8% overall (6%, 9%, 10% by dose) vs 3% placeboFDA labelFDA label (Foundayo)
Discontinuation due to adverse events6·1-9·9% vs 4·1% placeboHuman RCTn = 1613Lancet 2026, PMID 41275875
Discontinuation due to adverse events5.3 to 10.3% vs 2.7% placeboHuman RCTn = 3127The New England journal of medicine 2025, PMID 40960239
Discontinuation due to adverse events4.4 to 7.8% vs 1.4% placeboHuman RCTn = 559The New England journal of medicine 2025, PMID 40544435

What users report

Anecdotal evidence, 0 of 4

Side effects people describe from their own use of Orforglipron, quoted from 8 Reddit threads we read in r/Retatrutide, r/moreplatesmoredates and r/tirzepatidecompound (searched 11 Oct 2026). Each count is the number of different people in those threads, not how common the effect is. These reports are unverified: products bought outside a pharmacy are often mislabelled or impure, and many people take several compounds at once.

Nobody in these threads described a specific side effect from Orforglipron. That is a small sample, not evidence that it is safe.

A symptom others mention is not proof that it is harmless. If you have anything on the urgent list below, get care whatever others report.

What is not known

  • How common each effect is at the doses people use outside of studies.
  • Effects that take longer to appear than the length of the published studies.
  • How Orforglipron interacts with other medicines and supplements.
  • Whether research-grade products, which are not checked by the FDA, behave like the material used in studies.

When to get medical help

Get urgent care for: trouble breathing, swelling of the face or throat, a widespread rash, severe or lasting stomach pain, fainting, or an injection site that becomes hot, red and spreading.

This is not a complete list. A doctor or pharmacist can help you judge whether a symptom is related.

Discontinuations: label versus trials

The Foundayo label pools two trials and reports permanent stops by dose.[1]

In the ATTAIN-1 obesity trial, adverse events led to discontinuation in 5.3 to 10.3% of patients in the orforglipron groups and 2.7% on placebo.[7]

In the early type 2 diabetes trial, permanent discontinuation due to adverse events occurred in 4.4 to 7.8% on orforglipron and 1.4% on placebo.[8]

In the phase 2 obesity trial, gastrointestinal events led to discontinuation of orforglipron in 10 to 17% of participants across dose cohorts.[9]

Excess over placebo in percentage points: label pool 5 overall (3 at 5.5 mg, 6 at 9 mg, 7 at 17.2 mg); ATTAIN-1 range 2.6 to 7.6; early type 2 diabetes trial range 3.0 to 6.4.

Calculated from label 8, 6, 9, 10; label placebo 3; attain1 5.3, 10.3; attain1 placebo 2.7; t2d 4.4, 7.8; t2d placebo 1.4. Formula: orforglipron % minus placebo %

What the Foundayo label flags

The Foundayo label contraindicates use in people with a personal or family history of medullary thyroid carcinoma or with MEN 2.[1]

The label says the human relevance of the GLP-1 receptor-dependent thyroid C-cell tumors seen in rodents has not been determined for orforglipron.[1]

The label reports tachycardia in 3% of Foundayo-treated patients and 0.9% of those on placebo.[1]

In the pooled trials, the label reports cholelithiasis in 1% on Foundayo and 0.7% on placebo, and acute cholecystitis in 0.4% and 0.3%.[1]

Pregnancy and contraception

The label says to discontinue Foundayo when pregnancy is recognized.[1]

For oral hormonal contraceptives, the label advises switching to a non-oral method or adding a barrier method for 30 days after initiation and after each dose escalation.[1]

Common questions

What are the side effects of orforglipron?

The Foundayo label lists as most common (reported in at least 5% of treated patients) nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation, gastroesophageal reflux disease, flatulence and hair loss.[1]

What side effects do people who use Orforglipron report?

In the 8 Reddit threads we read (11 Oct 2026), nobody described a specific side effect from Orforglipron. That is a small sample, not evidence of safety.

Is Orforglipron safe?

Orforglipron has an FDA-approved label that lists its known risks. That label covers the approved product used as prescribed, not compounded or research-chemical versions.

Does orforglipron interact with other medicines?

The label's contraceptive advice covers 30 days after starting and after each dose escalation.[1]

How does orforglipron compare with oral semaglutide on stomach side effects?

In a head-to-head trial, gastrointestinal events occurred in 59% and 58% on orforglipron versus 37% and 45% on oral semaglutide.[3]

What are the contraindications for orforglipron?

The label contraindicates orforglipron with a personal or family history of medullary thyroid carcinoma or MEN 2, and with known serious hypersensitivity to orforglipron or its excipients.[1]

How long do orforglipron's stomach side effects last?

The label says nausea, vomiting and diarrhea were more frequent while the dose was being raised and became less frequent over time; it gives no day count.[1]

How severe were orforglipron's gastrointestinal reactions on the label?

Of patients who reported gastrointestinal reactions, 60% called them mild, 36% moderate and 4% severe.[1]

Does orforglipron cause pancreatitis?

In the pooled label trials, 6 adjudicated acute pancreatitis events occurred in 6 Foundayo-treated patients (0.14 per 100 years of exposure) versus 2 events in 1 placebo patient (0.04).[1]

How do I report a side effect from orforglipron (Foundayo)?

The label tells people to report suspected adverse reactions to Eli Lilly at 1-800-LillyRx (1-800-545-5979) or to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch; the full prescribing information is the DailyMed label cited on this page.[1]

More on Orforglipron

Sources

  1. 1These highlights do not include all the information needed to use FOUNDAYO safely and effectively. See full prescribing information for FOUNDAYO. FOUNDAYO (orforglipron) tablets, for oral use Initial FDA label (Foundayo), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  2. 2Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.Lancet (London, England) · 2026PMID 41275875Accessed 2 Oct 2026
  3. 3Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.Lancet (London, England) · 2026PMID 41765029Accessed 2 Oct 2026
  4. 4Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.Lancet (London, England) · 2026PMID 42259339Accessed 2 Oct 2026
  5. 5Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.Nature medicine · 2026PMID 42120723Accessed 2 Oct 2026
  6. 6Orforglipron for obesity treatment in older patients ≥65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials.Obesity pillars · 2026PMID 42577069Accessed 2 Oct 2026
  7. 7Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.The New England journal of medicine · 2025PMID 40960239Accessed 2 Oct 2026
  8. 8Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.The New England journal of medicine · 2025PMID 40544435Accessed 2 Oct 2026
  9. 9Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.The New England journal of medicine · 2023PMID 37351564Accessed 2 Oct 2026
  10. 10Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.Lancet (London, England) · 2023PMID 37369232Accessed 2 Oct 2026
  11. 11Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.Diabetes, obesity & metabolism · 2023PMID 37344954Accessed 2 Oct 2026
  12. 12Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.Diabetes, obesity & metabolism · 2023PMID 37264711Accessed 2 Oct 2026
  13. 13Effects of once-daily oral orforglipron on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials.Archives of endocrinology and metabolism · 2024PMID 39420937Accessed 2 Oct 2026

Found an error? Report a correction.